Address: Albert-Schweitzer-Gasse 3 1140 Vienna
,Austria
Tel: +43 1 97 007
Web: http://www.ratiopharm.at/de/pub/
In 1958, Ludwig Merckle GmbH in Vienna was founded as the first foreign branch of the German Merckle Arzneimittel GmbH. This was renamed ratiopharm Arzneimittel Vertriebs-GmbH 40 years later. In the years that followed, the company specialized in the marketing and sales of generic medication – copies of original pharmaceuticals already available made with identical active substances – as well as over-the-counter medicinal products (OTC medicines). Biotechnologically produced medicines (biologicals) for the supportive therapy of cancer patients have also been in the range since 2009. In 2011 the portfolio was supplemented by Copaxone® Austria’s leading treatment for multiple sclerosis as well as a range of oncology related drugs.
The ratiopharm Group was taken over by TEVA Pharmaceutical Industries in 2010. The TEVA corporation, which specializes in the development, production and sale of generics and innovative medications, the latter for the central nervous system, oncology, pain therapy and gynaecology, is one of the 15 largest pharmaceutical companies in the world and is the market leader in the medicinal treatment of multiple sclerosis. Since the acquisition of the Cephalon Group in 2011, TEVA- ratiopharm in Austria has been offering generic brands and popular OTC products such as ratioDolor® – lately also in a joint venture with Procter & Gamble – as well as a wide range of original products, making it one of the leading pharmaceutical companies in Austria.
TEVA-ratiopharm currently markets more than 170 products in Austria and moves around 16 Million packages per year. TEVA-ratiopharm is one of the country’s ten largest pharmaceutical companies with about ninety employees in 2012.
Dr Spatz, what would you highlight as the main specificities of the Austrian generic market, and explain how Teva has adapted its approach to the Austrian environment? Teva recently changed…
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative…
Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the rationale behind Austria’s prioritization of rare diseases and its leading role in the field.…
Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out,…
Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive footprint in the life sciences, its positioning as the start-up hub for Central and Eastern…
Peter Wimmer, country manager of Angelini Austria and Germany, discusses the tailored long-term strategy that this exciting Italian pharmaceutical company is implementing to establish a boutique portfolio and the importance…
Christoph Wahl and Gerlad Weirowski of DHL Global Forwarding Austria discuss the significance of the Austrian affiliate being chosen as lead office for CEE and the company’s life sciences and…
Christoph Sauermann, managing director of Mediclass, an innovative healthcare center, discusses how the complexities of the Austrian healthcare system can be solved through primary healthcare centers, such as Mediclass. Furthermore,…
Rudolf Widmann, CEO and founder of AOP Orphan, the first rare disease-specific European company, discusses the overriding goal to ensure rare disease patients are matched with the correct treatments and…
Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human protein products manufacturer in the world, discuss the strategic significance of Austria to the…
Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations.…
David Kasper, CEO of ARCHIMEDlife, an innovative Austrian company focused on novel laboratory diagnostics, discusses the innovative solution of a dried blood sample in daily routine diagnostics and novel assays…
See our Cookie Privacy Policy Here
